Lipidio is focused on advancing a molecule to treat diseases associated with excess body fat including non-alcoholic steatohepatitis (NASH), Prader-Willi syndrome (PWS) and antipsychotic drug-induced weight gain (AIWG), which represent major unmet medical needs. Lipidio Pharma maintains its headquarters in San Diego, CA.

X-Vax Technology, Inc. is a biotech company committed to developing vaccines against pathogens acquired by mucosal infection such as herpes. Their research leads us to believe that the new approach they are taking could succeed in defeating herpes. They have created a herpes vaccine candidate called ∆gD-2 (delta gD-2) because it is based on an HSV-2 virus genetically deleted for glycoprotein D (gD-2). With it, they have been able to prevent infections caused by herpes type 1 (HSV-1) and type 2 (HSV-2) in multiple preclinical models—with encouraging results. The vaccine induces Fc receptor activating antibodies that mediate antibody-dependent cell-mediated killing (ADCK) as the primary mechanism of protection. ADCK is induced to flag infected cells for destruction by natural immune cells.

Elucida Oncology, Inc.™ is a biotechnology company focused on clinical research, development and subsequent commercialization of life-changing products based on the Target or Clear™ technology of our novel, ultra-small nanoparticle delivery platform. Our work is centered around the detection and treatment of primary solid tumor and metastatic cancers. Our goal is to leverage our novel platform to extend and enhance as many lives as we can.

Nacuity Pharmaceuticals, Inc. was formed to focus on bringing a potential treatment with NACA to patients with RP (Retinitis Pigmentosa) guided by the groundbreaking work of Dr. Peter Campochiaro, MD, at the Wilmer Institute of Johns Hopkins University.

Aridis is a privately held biotechnology company focused on developing new breakthrough therapies for infectious diseases and addressing the growing problem of antibiotic resistance. Aridis has a deep, diversified portfolio of clinical and pre-clinical stage anti-infective product candidates that are complimented by a fully human monoclonal antibody discovery platform technology. 

Alveo is a technology-platform company focused on developing rapid, reliable, and economical cloud-based diagnostics for use by anyone, anytime, anywhere.

Centrexion is a Baltimore-based pharmaceutical development company seeking to develop a new class of therapeutics that stops pain at its source. Their non-opioid, clinical stage product candidates selectively deactivate pain fibers to provide patients with long lasting relief. Their pipeline targets major unmet needs in the treatment of severe pain caused by human osteoarthritis, or OA, and canine OA, nerve injury, and herpes zoster viral infection.

Cerecor Inc. is a Maryland-based biopharmaceutical company comprised of a team of industry experts and leading scientists focused on developing neuroscience drugs that make a difference. They are committed to improving the lives of patients and prioritize underserved segments of common diseases. Cerecor exclusively develops products for which human proof-of-concept has been demonstrated and possess biomarkers to guide development. The company’s clinical strategies employ the latest technologies to improve the signal-to-noise ratio and likelihood of trial success.  Current product opportunities are being developed as first-in-class, best-in-class drug candidates in depression and cognitive disorders, including schizophrenia.

ContraFect Corporation, a New York-based biotechnology company, has assembled one of the most talented management and scientific teams in the industry. They are committed to developing technologies, treatments, and products that will target and kill the most virulent and resistant microorganisms—including gram-positive bacteria, such as Staphylococcus (MRSA), and viruses, such as Influenza.

Edge Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing life-saving hospital products that improve patient outcome by addressing acute, fatal or debilitating conditions that have no current effective treatment. These delayed complications occur days to weeks after different types of brain hemorrhages (ruptured brain aneurysms, chronic subdural hematoma, subarachnoid and intracerebral hemorrhage and head trauma).

A clinical-stage oncology company developing best-in-class oral small molecule CXCR4 antagonists for the treatment of refractory solid tumors. We will deliver game-changing clinical benefit for these severely affected patients, bringing new hope to underserved cancers. X4 is developing two unique programs: our drug candidate, X4P-001, has clinical experience in over 70 subjects and is advancing into Phase 1/2 trials in refractory clear cell renal cell carcinoma (ccRCC) and refractory epithelial ovarian cancer (EOC). Our second program, X4P-002, is a unique series of late lead molecules that penetrate the blood brain barrier. We will pursue early clinical development in glioblastoma multiforme (GBM), a rare form of lethal brain cancer, for the X4P-002 program.

Sapience Therapeutics is a preclinical-stage biotechnology company focused on advancing novel therapeutics for major unmet medical needs, particularly high mortality cancers. Our drug development program involves translating science into novel therapies, and our initial goal is to develop a first-in-class treatment for glioblastoma multiforme (GBM), which is the most severe and deadly form of brain cancer.